Piper Sandler raised the firm’s price target on Bristol Myers (BMY) to $75 from $66 and keeps an Overweight rating on the shares. The firm says it remains bullish even amid a considerable rally. Piper believes there are two broad avenues to a return to top-line growth following the Eliquis U.S. loss of exclusivity in 2028, namely milvexian success in the LIBREXIA AF study in atrial fibrillation; or a drumbeat of singles, doubles and triples, to borrow from baseball parlance, associated with the rest of the pipeline.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- BMY’s Mavacamten Safety Extension Wraps Up, Sharpening the Long-Term Outlook in Hypertrophic Cardiomyopathy
- Barclays Bank (BCS) Names Four Pharma Stocks to Buy Now
- Bristol Myers initiated with an Overweight at Barclays
- FDA to begin requiring on clinical trial
- FDA to begin requiring one clinical trial in drug approvals